


Available online on 15.02.2026 at <http://ajprd.com>

Asian Journal of Pharmaceutical Research and Development

Open Access to Pharmaceutical and Medical Research

© 2013-25, publisher and licensee AJPRD, This is an Open Access article which permits unrestricted non-commercial use, provided the original work is properly cited

Open  Access

Review Article

A Review Article on Rheumatoid Arthritis (RA)

Shaziya Tanzeem .T*, Shaguftha .T, Farida Banu .S, Karishma .S, Hina Tousif .S, Banny .S.V, Sameera .P, Meena .G.,

Department of Pharmacy, Sri Lakshmi Venkateshwara Institute of Pharmaceutical Sciences, Proddatur, Kadapa District, Andhra Pradesh, India.

ABSTRACT

Rheumatoid arthritis (RA) is a chronic systemic autoimmune inflammatory disorder primarily affecting synovial joints and leading to progressive joint destruction, disability, and reduced quality of life. In addition to joint involvement, RA is associated with multiple extra-articular manifestations involving the cardiovascular, pulmonary, ocular, and nervous systems. The etiology of RA is multifactorial, involving genetic predisposition, environmental factors such as smoking, and immune dysregulation. This review article provides a comprehensive overview of rheumatoid arthritis, including its historical background, etiology, pathophysiology, clinical manifestations, diagnostic criteria, and current therapeutic strategies. Special emphasis is given to the role of cytokines, immune cells, autoantibodies, and inflammatory mediators in disease progression. The review also discusses conventional and biological disease-modifying antirheumatic drugs (DMARDs), their mechanisms of action, and associated adverse effects. Understanding the complex pathogenesis and evolving treatment options of RA is essential for improving disease management, minimizing complications, and enhancing patient outcomes.

KEYWORDS: Rheumatoid arthritis; Autoimmune disease; Inflammation; Pathophysiology; DMARDs; Biological therapy

ARTICLE INFO: Received 10 Nov. 2025; Review Complete 26 Dec. 2025; Accepted 10 Jan. 2026; Available online 15 Feb. 2026



Cite this article as:

Shaziya Tanzeem .T, Department of Pharmacy, Sri Lakshmi Venkateshwara Institute of Pharmaceutical Sciences, Proddatur, Kadapa District, Andhra Pradesh, India., Asian Journal of Pharmaceutical Research and Development. 2026; 14(1):65-71, DOI: <http://dx.doi.org/10.22270/ajprd.v14i1.11699>

*Address for Correspondence:

Shaziya Tanzeem .T, Department of Pharmacy, Sri Lakshmi Venkateshwara Institute of Pharmaceutical Sciences, Proddatur, Kadapa District, Andhra Pradesh, India.

INTRODUCTION

Rheumatoid Arthritis (RA)

Rheumatoid arthritis (RA) is defined as a systemic autoimmune pathology associated with a chronic inflammatory process, which can damage both joints and extra-articular organs, including the heart, kidney, lung, digestive system, eye, skin and nervous system [1,2]. Numerous types of arthritis have been investigated and described in order to classify them into non-inflammatory arthritis (osteoarthritis) and inflammatory arthritis caused by crystal deposition (pseudogout, basic calcium phosphate disease, gout), by bacterial and viral infections (Staphylococcus aureus, Neisseria gonorrhoea, complications of Lyme disease, Parvovirus, Enterovirus) or by autoimmune processes.

Although a number of biomolecular mechanisms have been proposed, the etiology of RA is not yet fully elucidated, a current hypothesis being that dysregulated citrullination leads to the production of anti-citrullinated protein antibodies (ACPAs) [3,4]. The evolution of RA is fluctuant with episodic exacerbations and in the absence of optimal treatment symptoms gradually worsen until the joints are irreversibly damaged and physical and psychological functioning is affected [5]. Moreover, RA complications and comorbidities reduce the life expectancy of patients by a few years [6].

Existing statistical analysis and interpretation of quantitative data show that RA represents not only a medical feature, but also a public health issue. The most common medical cause of mobility-related functionality loss among United States (US) adults is arthritis [7,8]. Furthermore, several health economic studies have measured the economic burden of RA

and, and as a result, have demonstrated that the costs of preventing RA by reducing the risk factors or treating incipient cases are much lower than those generated by hospitalization and surgeries[9,10].

Origins of rheumatoid arthritis

Although intermittent case series were subsequently reported, the disease was not fully recognized until it was defined by Garrod in 1859. He named it 'rheumatoid' arthritis to

distinguish it from the two well-known forms arthritis, rheumatic fever and gout. By the early 20th century, RA was viewed as separate from osteoarthritis ('arthritis deformans'). In 1957, Charles Short described RA definitively and clearly set it apart as a defined clinical entity distinct from the seronegative spondyloarthropathies, crystal-induced disease, osteoarthritis, systemic lupus erythematosus, and many other conditions.




Figure 23: Synovial histology in rheumatoid arthritis.

Synovial histology in rheumatoid arthritis. A photomicrograph (magnification x 200) shows the redundant folds of the synovial lining and intense infiltration with inflammatory cells in RA. The intimal lining layer (solid arrow) is hyperplastic, with multiple layers of cells compared with a normal lining that is one or two cell layers deep. The sublining region (dashed arrow) is marked by accumulation of mononuclear cells such as CD4+T cells, macrophages and B cells[11,12]

Etiology

- The etiology of RA has a significant basis in genetics. It is thought to result from the interaction between patients' genotypes and environmental factors[13].
- The risk of developing rheumatoid arthritis has been associated with HLA-DRB1 alleles: HLA-DRB1*04, HLA-DRB1*01, and HLA-DRB1*10. These HLA-DRB1 alleles contain a stretch of a conserved sequence of 5 amino acids referred to as the "shared epitope" (SE) in the third hypervariable region of their DRB1 chain,

which has been associated with the risk of developing RA[14-17].

- Some genetic polymorphisms are associated with RA in different ethnic groups [16,18].
- Cigarette smoking is the strongest environmental risk factor associated with rheumatoid arthritis. Studies have shown in anti-citrullinated protein antibody (anti-CCP) positive individuals, there is an interaction between the shared epitope (SE) and smoking that increases the risk of RA[19-25]
- Other environmental triggers may play a role as a trigger for RA, these include silica, asbestos, textile dust, and P gingivalis may be entered through mouth ,lungs and gut[26].
- Changes in the composition and function of the intestinal microbiome have been related to rheumatoid arthritis as well[23].




Figure 24: Immunological processes in the pre-RA phase. ACPA, anti-citrullinated protein antibodies; APC, antigen-presenting cells; RF, rheumatoid factor [27]

Pathophysiology

- RA risk is influenced by a genetic predisposition, environmental factors, or a combination of both. It is clear that immune cells, such as lymphocytes, neutrophils, and macrophages, play an important role in the pathophysiology of RA [28].
- Within the synovium of RA patients are macrophages and T cells that produce cytokines which promote inflammation and cell migration.
- Cytokines tumor necrosis factor- α (TNF- α), interleukin-1 (IL-1), and interleukin-6 (IL-6), produced by macrophages, and cytokine interleukin-17 (IL-17), produced by CD4+ cells, are commonly involved in the inflammatory response and subsequent cartilage destruction.
- These cytokines activate synoviocytes and cause them to proliferate, creating proteases in the synovial fluid, which lead to the breakdown of cartilage and hypertrophied synovial tissue, known as pannus [29].
- Pannus can be further exacerbated by angiogenesis. The additional blood supply to invaded cartilage and bone allows immune cells to infiltrate the joints, worsening the synovial hyperplasia [28].
- Cytokines also combine with receptor activator of nuclear factor kappa- β ligand (RANKL) to stimulate osteoclast activity, which leads to bone erosion. The expression of RANKL is also affected by T cells [30].
- Synovial dendritic cells stimulate immune response by attracting T lymphocytes and activating antigen-specific T cells and, in turn, B cells. In this positive feedback loop, activated B cells stimulate CD4+ T cells, producing more cytokines [31,32].
- B cell proliferation can also lead to the creation of plasma cells, which produce autoantibodies, including rheumatoid factor (RF) and anti-citrullinated protein antibodies (ACPAs) [33].
- These autoantibodies infiltrate the joint through newly developed blood vessels and are currently used in the diagnosis and prognosis of RA [34].




Figure 25: The immune processes that occur in the joint synovium and synovial fluid, leading to the progress of bone erosion and cartilage degeneration [35,36]

Signs and symptoms

- The most common and predominant symptoms include joint pain and swelling. Initial joint involvement is typically in the small joints of the hands and feet, followed by larger joints. One of the hallmarks is stiffness, particularly morning stiffness [37].
- Usually, the onset of symptoms is slow and insidious; however, in some cases, an episodic pattern of symptoms can be seen and is defined as palindromic rheumatism [38].
- Although multiple small joint involvements are a frequent feature, some patients may present with monoarticular and extra articular involvement (lungs).
- typical signs and symptoms of carpal tunnel syndrome
- The classical physical findings of ulnar deviation, metacarpophalangeal joint subluxation, ulnar deviation, swan neck deformity, Boutonniere deformity, and the "bowstring" sign are seen in advanced chronic disease.
- Other findings in the later stages of RA include a reduced range of motion in the shoulders, elbows, and knees. In the feet, hallux valgus is common, as well as other toe deformities [39].
- Rheumatoid nodules are the most common extra articular manifestations of RA [40]. They are commonly found on pressure points such as the olecranon but may also occur over the joints of the hands and feet, the patella, and the Achilles tendons.

- Interstitial lung disease (ILD) affects 5 to 16% of patients with RA and is associated RA specific auto antibodies and increased mortality[41-43].
- Ophthalmological manifestations include secondary Sjogren syndrome with dry eyes and also dry mouth[44].
- Similarly, Felty syndrome, which is the combination of long-standing seropositive RA (including RF and ANA), leukopenia, and splenomegaly, is rarely seen today.
- These patients may have chronic non-healing ulcers and an increased risk of bacterial infection. Vasculitis involving both medium and small-sized blood vessels can also be seen as a presenting symptom of RA.[45]

Diagnosis and assessment

The presence of tenosynovitis, eg, at the flexor carpi ulnaris tendon, and subclinical synovial inflammation can be detected by imaging with color Doppler sonography or gadolinium-enhanced magnetic resonance imaging, which demonstrate expansion of intra-articular soft tissue or hypervascularization of the synovial membrane.

No diagnostic criteria exist for RA [46,47]

The classification of RA requires presence of at least 1 clinically swollen joint and at least 6 of 10 points from a scoring system (Table 1).

Table.1: Rheumatoid arthritis classification

Category	Criteria	Points
Joint Distribution (0–5 points)	1 large joint	0
	2–10 large joints	1
	1–3 small joints (large joints not counted)	2
	4–10 small joints (large joints not counted)	3
	>10 joints (≥1 small joint)	5
Serology (0–3 points)	Negative RF and negative ACPA	0
	Low positive RF or low positive ACPA	2
	High positive RF or high positive ACPA	3
Symptom Duration (0–1 point)	< 6 weeks	0
	≥ 6 weeks	1
Acute Phase Reactants (0–1 point)	Normal CRP and normal ESR	0
	Abnormal CRP or abnormal ESR	1

Joint involvement based on physical examination or imaging by ultrasound or magnetic resonance imaging contributes up to 5 points; elevated levels of RF, ACPAs, or both provides 2 additional points (or 3 points with levels >3 times the upper limit of normal); and elevated acute phase reactant (APR) response, such as increased

CRP level or erythrocyte sedimentation rate, and duration of symptoms (<6 weeks) provide 1 additional point each. These 2010 criteria have a sensitivity of 82% and specificity of 61%. Sensitivity of the new classification criteria was 11% greater and specificity 4% lower compared with the 1987 criteria[48].

Clinical management and treatment:[49-62]

Category	Drugs	Mechanism	Side effects
Symptomatic treatment: 1.NSAIDs	<ul style="list-style-type: none"> • Naproxen, • ibuprofen 	Inhibition of COX enzyme	Bleeding, GI ulcerations, renal failure, rashes, confusion ...etc
	<ul style="list-style-type: none"> • celecoxib, • valdecoxib 	Inhibition of COX-II enzyme	Nausea,Diarrhea..Etc
	<ul style="list-style-type: none"> • hydrocortisone • prednisolone • dexamethasone 	Immune-suppressor	Long Term Side Effects Include , Weight Gain, Myalgia, Diabetes, Bone Thinning
Disease modifying anti-rheumatoid drugs (DMARDs)treatment: 1.Conventional DMARDs:	<ul style="list-style-type: none"> • Methotrexate • Leflunomide • Hydroxy Chloro- • Quine • Sulfasalazine 	Non-targeted suppression of the over reactive Immune response	Diarrhoea, Nausea, Liver Damage, Thrombocytopenia, Leukopenia...Etc
	2.Biological DMARDs:		

	<ul style="list-style-type: none"> • Etanercept • Infliximab • Adalimumab • Golimumab 	Inhibition of TNF-alpha	Herpes zoster, Hepatitis-B/C, Bone marrow - Suppression, Hepatotoxicity, Skin cancers ...etc.
	<ul style="list-style-type: none"> • Anakinra • Tocilizumab 	Inhibition of interleukins	
	<ul style="list-style-type: none"> • Rituximab 	Depletion of B-cells	
	<ul style="list-style-type: none"> • Abatacept 	Antagonism of T-cells	

REFERENCES

- Conforti, A.; di Cola, I.; Pavlych, V.; Ruscitti, P.; Berardicurti, O.; Ursini, F.; Giacomelli, R.; Cipriani, P. Beyond the joints, the extra-articular manifestations in rheumatoid arthritis. *Autoimmun. Rev.* 2021, 20, 102735. [Google Scholar] [CrossRef]
- Cojocaru, M.; Cojocaru, I.M.; Silosi, I.; Vrabie, C.D.; Tanasescu, R. Extra-articular manifestations in rheumatoid arthritis. *Mădica* 2010, 5, 286–291. [Google Scholar] [PubMed]
- Joseph, A.; Brasington, R.; Kahl, L.; Ranganathan, P.; Cheng, T.P.; Atkinson, J. Immunologic rheumatic disorders. *J. Allergy Clin. Immunol.* 2010, 125, S20S215. [Google Scholar] [CrossRef]
- Kurowska, W.; Kuca-Warnawin, E.H.; Radzikowska, A.; Maśliński, W. The role of anti-citrullinated protein antibodies (ACPA) in the pathogenesis of rheumatoid arthritis. *Cent. J. Immunol.* 2017, 42, 390–398. [Google Scholar] [CrossRef]
- Wegner, N.; Lundberg, K.; Kinloch, A.; Fisher, B.; Malmström, V.; Feldmann, M.; Venables, P.J. Autoimmunity to specific citrullinated proteins gives the first clues to the etiology of rheumatoid arthritis. *Immunol. Rev.* 2010, 233, 34–54. [Google Scholar] [CrossRef]
- Chaurasia, N.; Singh, A.; Singh, I.L.; Singh, T.; Tiwari, T. Cognitive dysfunction in patients of rheumatoid arthritis. *J. Fam. Med. Prim. Care* 2020, 9, 2219–2225. [Google Scholar] [CrossRef]
- Lassere, M.N.; Rappo, J.; Portek, I.J.; Sturgess, A.; Edmonds, J.P. How many life years are lost in patients with rheumatoid arthritis? Secular cause-specific and all-cause mortality in rheumatoid arthritis, and their predictors in a long-term Australian cohort study. *Intern. Med. J.* 2013, 43, 66–72. [Google Scholar] [CrossRef] [PubMed]
- Hootman, J.M.; Helmick, C.G.; Brady, T.J. A public health approach to addressing arthritis in older adults: The most common cause of disability. *Am. J. Public Health* 2012, 102, 426–433. [Google Scholar] [CrossRef] [PubMed]
- Theis, K.A.; Steinweg, A.; Helmick, C.G.; Courtney-Long, E.; Bolen, J.A.; Lee, R. Which one? What kind? How many? Types, causes, and prevalence of disability among U.S. adults. *Disabil. Health J.* 2019, 12, 411–421. [Google Scholar] [CrossRef]
- Lanes, S.F.; Lanza, L.L.; Radensky, P.W.; Yood, R.A.; Meenan, R.F.; Walker, A.M.; Dreyer, N.A. Resource utilization and cost of care for rheumatoid arthritis and osteoarthritis in a managed care setting. The importance of drug and surgery costs. *Arthritis Rheum.* 1997, 40, 1475–1481. [Google Scholar] [CrossRef]
- Aceves-Avila, F. J., Baez-Molgado, S., Medina, F. & Fraga, A. Paleopathology in osseous remains from the 16th century. A survey of rheumatic diseases. *J. Rheumatol.* 25, 776–782 (1998).
- Rothschild, B. M., Turner, K. R. & DeLuca, M. A. Symmetrical erosive peripheral polyarthritis in the Late Archaic Period of Alabama. *Science* 241, 1498–1501 (1988).
- Silman AJ, MacGregor AJ, Thomson W, Holligan S, Carthy D, Farhan A, Ollier WE. Twin concordance rates for rheumatoid arthritis: results from a nationwide study. *Br J Rheumatol.* 1993 Oct;32(10):903-7. [PubMed]
- Gregersen PK, Silver J, Winchester RJ. The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. *Arthritis Rheum.* 1987 Nov;30(11):1205-13. [PubMed]
- Weyand CM, Hicok KC, Conn DL, Goronzy JJ. The influence of HLA-DRB1 genes on disease severity in rheumatoid arthritis. *Ann Intern Med.* 1992 Nov 15;117(10):801-6. [PubMed]
- Teil Espina M, Gabarrini G, Harmsen HJM, Westra J, van Winkelhoff AJ, van Dijk JM. Talk to your gut: the oral-gut microbiome axis and its immunomodulatory role in the etiology of rheumatoid arthritis. *FEMS Microbiol Rev.* 2019 Jan 01;43(1):1-18. [PubMed]
- Wu H, Liao W, Li Q, Long H, Yin H, Zhao M, Chan V, Lau CS, Lu Q. Pathogenic role of tissue-resident memory T cells in autoimmune diseases. *Autoimmun Rev.* 2018 Sep;17(9):906-911. [PubMed]
- Ciccacci C, Conigliaro P, Perricone C, Rufini S, Triggianese P, Politi C, Novelli G, Perricone R, Borgiani P. Polymorphisms in STAT-4, IL-10, PSORS1C1, PTPN2 and MIR146A genes are associated differently with prognostic factors in Italian patients affected by rheumatoid arthritis. *Clin Exp Immunol.* 2016 Nov;186(2):157-163. [PMC free article] [PubMed]
- Stolt P, Bengtsson C, Nordmark B, Lindblad S, Lundberg I, Klareskog L, Alfredsson L., EIRA study group. Quantification of the influence of cigarette smoking on rheumatoid arthritis: results from a population based case-control study, using incident cases. *Ann Rheum Dis.* 2003 Sep;62(9):835-41. [PMC free article] [PubMed]
- Padyukov L, Silva C, Stolt P, Alfredsson L, Klareskog L. A gene-environment interaction between smoking and shared epitope genes in HLA-DR provides a high risk of seropositive rheumatoid arthritis. *Arthritis Rheum.* 2004 Oct;50(10):3085-92. [PubMed]
- Linn-Rasker SP, van der Helm-van Mil AH, van Gaalen FA, Kloppenburg M, de Vries RR, le Cessie S, Breedveld FC, Toes RE, Huizinga TW. Smoking is a risk factor for anti-CCP antibodies only in rheumatoid arthritis patients who carry HLA-DRB1 shared epitope alleles. *Ann Rheum Dis.* 2006 Mar;65(3):366-71. [PMC free article] [PubMed]
- Klareskog L, Stolt P, Lundberg K, Källberg H, Bengtsson C, Grunewald J, Rönnelid J, Harris HE, Ulfgrén AK, Rantapää-Dahlqvist S, Eklund A, Padyukov L, Alfredsson L. A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to

- autoantigens modified by citrullination. *Arthritis Rheum.* 2006 Jan;54(1):38-46. [PubMed]
23. Lundström E, Källberg H, Alfredsson L, Klareskog L, Padyukov L. Gene-environment interaction between the DRB1 shared epitope and smoking in the risk of anti-citrullinated protein antibody-positive rheumatoid arthritis: all alleles are important. *Arthritis Rheum.* 2009 Jun;60(6):1597-603. [PMC free article] [PubMed]
 24. Sugiyama D, Nishimura K, Tamaki K, Tsuji G, Nakazawa T, Morinobu A, Kumagai S. Impact of smoking as a risk factor for developing rheumatoid arthritis: a meta-analysis of observational studies. *Ann Rheum Dis.* 2010 Jan;69(1):70-81. [PubMed]
 25. Derksen VFAM, Huizinga TWJ, van der Woude D. The role of autoantibodies in the pathophysiology of rheumatoid arthritis. *Semin Immunopathol.* 2017 Jun;39(4):437-446. [PMC free article] [PubMed]
 26. Klareskog L, Rönnelid J, Saevarsdottir S, Padyukov L, Alfredsson L. The importance of differences; On environment and its interactions with genes and immunity in the causation of rheumatoid arthritis. *J Intern Med.* 2020 May;287(5):514-533. [PubMed]
 27. Essouma, M.; Noubiap, J.J.N. Is air pollution a risk factor for rheumatoid arthritis? *J. Inflamm.* 2015, 12, 48. [Google Scholar] [CrossRef] [Green Version]
 28. Choy E. Understanding the dynamics: pathways involved in the pathogenesis of rheumatoid arthritis. *Rheumatology.* (2012) 51(Suppl. 5):v3-11. doi: 10.1093/rheumatology/kes113
 29. Byng-Maddick R, Ehrenstein MR. The impact of biological therapy on regulatory T cells in rheumatoid arthritis. *Rheumatology.* (2015) 54:768-75. doi: 10.1093/rheumatology/keu487
 30. Smolen JS, Aletaha D, Barton A, Burmester GR, Emery P, Firestein GS, et al. Rheumatoid arthritis. *Nat Rev Dis Prim.* (2018) 4:18001. doi: 10.1038/nrdp.2018.1
 31. Tran CN, Lundy SK, Fox DA. Synovial biology and T cells in rheumatoid arthritis. *Pathophysiology.* (2005) 12:183-9. doi: 10.1016/j.pathophys.2005.07.005
 32. Bugatti S, Vitolo B, Caporali R, Montecucco C, Manzo A. B cells in rheumatoid arthritis: from pathogenic players to disease biomarkers. *Res Article Bio Med Res Int.* (2014) 2014:681678. doi: 10.1155/2014/681678
 33. Silverman GJ, Carson DA. Roles of B cells in rheumatoid arthritis. *ArthrResTher.* (2003) 5(Suppl. 4):S1-6. doi: 10.1186/ar1010
 34. Boissier MC, Semerano L, Challal S, Saidenberg-Kermanac'h N, Falgarone G. Rheumatoid arthritis: from autoimmunity to synovitis and joint destruction. *J Autoimm.* (2012) 39:222-8. doi: 10.1016/j.jaut.2012.05.021
 35. Derksen VFAM, Huizinga TWJ, van der Woude D. The role of autoantibodies in the pathophysiology of rheumatoid arthritis. *Semin Immunopathol* (2017) 39(4):437-46. doi: 10.1007/s00281-017-0627-z PubMed Abstract | CrossRef Full Text | Google Scholar
 36. Giles JT. Extra-articular manifestations and comorbidity in rheumatoid arthritis: Potential impact of pre-rheumatoid arthritis prevention. *Clin Ther* (2019) 41(7):1246-55. doi: 10.1016/j.clinthera.2019.04.01 PubMed Abstract | CrossRef Full Text | Google Scholar
 37. Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. *Lancet.* 2016 Oct 22;388(10055):2023-2038. [PubMed]
 38. Lee DM, Weinblatt ME. Rheumatoid arthritis. *Lancet.* 2001 Sep 15;358(9285):903-11. [PubMed]
 39. Sparks JA. Rheumatoid Arthritis. *Ann Intern Med.* 2019 Jan 01;170(1):ITC1-ITC16. [PubMed]
 40. Sayah A, English JC. Rheumatoid arthritis: a review of the cutaneous manifestations. *J Am Acad Dermatol.* 2005 Aug;53(2):191-209; quiz 210-2. [PubMed]
 41. Bongartz T, Nannini C, Medina-Velasquez YF, Achenbach SJ, Crowson CS, Ryu JH, Vassallo R, Gabriel SE, Matteson EL. Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study. *Arthritis Rheum.* 2010 Jun;62(6):1583-91. [PMC free article] [PubMed]
 42. Sparks JA, Jin Y, Cho SK, Vine S, Desai R, Doyle TJ, Kim SC. Prevalence, incidence and cause-specific mortality of rheumatoid arthritis-associated interstitial lung disease among older rheumatoid arthritis patients. *Rheumatology (Oxford).* 2021 Aug 02;60(8):3689-3698. [PMC free article] [PubMed]
 43. Samhuri BF, Vassallo R, Achenbach SJ, Kronzer VL, Davis JM, Myasoedova E, Crowson CS. Incidence, Risk Factors, and Mortality of Clinical and Subclinical Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Population-Based Cohort. *Arthritis Care Res (Hoboken).* 2022 Dec;74(12):2042-2049. [PMC free article] [PubMed]
 44. Conforti A, Di Cola I, Pavlych V, Ruscitti P, Berardicurti O, Ursini F, Giacomelli R, Cipriani P. Beyond the joints, the extra-articular manifestations in rheumatoid arthritis. *Autoimmun Rev.* 2021 Feb;20(2):102735. [PubMed]
 45. Abdulqader Y, Al-Ani M, Parperis K. Rheumatoid vasculitis: early presentation of rheumatoid arthritis. *BMJ Case Rep.* 2016 Nov 08;2016 [PMC free article] [PubMed]
 46. Aletaha D, Neogi T, Silman A, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. *Ann Rheum Dis.* 2010;69:1580-1588. doi:10.1136/ard.2010.138461
 47. Radner H, Neogi T, Smolen JS, Aletaha D. Performance of the 2010 ACR/EULAR classification criteria for rheumatoid arthritis: a systematic literature review. *Ann Rheum Dis.* 2014;73(1):114-123. doi:10.1136/annrheumdis-2013-203284
 48. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. *Arthritis Rheum.* 2005;52(11):3381-3390. doi:10.1002/art.21405
 49. Fraenkel, L.; Bathon, J.M.; England, B.R.; St. Clair, E.W.; Arayssi, T.; Carandang, K.; Deane, K.D.; Genovese, M.; Huston, K.K.; Kerr, G.; et al. American college of rheumatology guideline for the treatment of rheumatoid arthritis. *Arthritis Care Res.* 2021, 73, 924-939. [Google Scholar] [CrossRef]
 50. Smolen, J.S.; Landewé, R.B.M.; Bijlsma, J.W.J.; Burmester, G.R.; Dougados, M.; Kerschbaumer, A.; McInnes, I.B.; Sepriano, A.; van Vollenhoven, R.F.; de Wit, M.; et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. *Ann. Rheum. Dis.* 2020, 79, 685-699. [Google Scholar] [CrossRef] [Green Version]
 51. Moura, M.D.G.; Lopes, L.C.; Silva, M.T.; Barberato-Filho, S.; Motta, R.H.L.; Bergamaschi, C.C. Use of steroid and nonsteroidal anti-inflammatories in the treatment of rheumatoid arthritis: Systematic review protocol. *Medicine* 2018, 97, e12658. [Google Scholar] [CrossRef]
 52. Crofford, L.J. Use of NSAIDs in treating patients with arthritis. *Arthritis Res. Ther.* 2013, 15, S2. [Google Scholar] [CrossRef] [PubMed] [Green Version]
 53. Bullock, J.; Rizvi, S.A.A.; Saleh, A.M.; Ahmed, S.S.; Do, D.P.; Ansari, R.A.; Ahmed, J. Rheumatoid arthritis: A brief overview of the treatment. *Med. Princ. Pract.* 2019, 27, 501-507. [Google Scholar] [CrossRef]
 54. Monti, S.; Klersy, C.; Gorla, R.; Sarzi-Puttini, P.; Atzeni, F.; Pellerito, R.; Fusaro, E.; Paolazzi, G.; Rocchetta, P.A.; Favalli, E.G.; et al. Factors influencing the choice of first- and second-line biologic therapy for the treatment of rheumatoid arthritis: Real-

- life data from the Italian LORHEN registry. *Clin. Rheumatol.* 2017, 36, 753–761. [Google Scholar] [CrossRef] [Green Version]
55. Bywall, K.S.; Kihlbom, U.; Hansson, M.; Falahee, M.; Raza, K.; Baecklund, E.; Veldwijk, J. Patient preferences on rheumatoid arthritis second-line treatment: A discrete choice experiment of Swedish patients. *Arthritis Res. Ther.* 2020, 22, 1–10. [Google Scholar] [CrossRef] [PubMed]
56. Wang, W.; Zhou, H.; Liu, L. Side effects of methotrexate therapy for rheumatoid arthritis: A systematic review. *Eur. J. Med. Chem.* 2018, 158, 502–516. [Google Scholar] [CrossRef] [PubMed]
57. Van Vollenhoven, R.F. New therapeutic approaches in rheumatoid arthritis. *Presse Med.* 2016, 45, 179–192. [Google Scholar] [CrossRef] [PubMed]
58. Fassmer, A.M.; Garbe, E.; Schmedt, N. Frequency and trends of disease-modifying antirheumatic drug (DMARD) use in Germany. *Pharmacol. Res. Perspect.* 2016, 4, e00254. [Google Scholar] [CrossRef]
59. Aletaha D, Smolen JS. Diagnosis and Management of Rheumatoid Arthritis: A Review. *JAMA.* 2018 Oct 02;320(13):1360-1372. [PubMed]
60. Wang W, Zhou H, Liu L. Side effects of methotrexate therapy for rheumatoid arthritis: A systematic review. *Eur J Med Chem.* 2018 Oct 05;158:502-516. [PubMed]
61. Oo WM, Yu SP, Daniel MS, Hunter DJ. Disease-modifying drugs in osteoarthritis: current understanding and future therapeutics. *Expert Opin Emerg Drugs.* 2018 Dec;23(4):331-347. [PubMed]
62. Hughes CD, Scott DL, Ibrahim F., TITRATE Programme Investigators. Intensive therapy and remissions in rheumatoid arthritis: a systematic review. *BMC Musculoskelet Disord.* 2018 Oct 30;19(1):389. [PMC free article] [PubMed]

